Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study
Open Access
- 1 January 2015
- journal article
- research article
- Published by Hindawi Limited in Multiple Sclerosis International
- Vol. 2015, 1-5
- https://doi.org/10.1155/2015/369348
Abstract
Cortical lesions (CLs) and atrophy are pivotal in multiple sclerosis (MS) pathology. This study determined the effect of disease modifying drugs (DMDs) on CL development and cortical atrophy progression in patients with relapsing-remitting MS (RRMS) over 48 months. Patients () were randomized to sc IFNβ-1a 44 μg, im IFNβ-1a 30 μg, or glatiramer acetate 20 mg. The reference population comprised 50 DMD-untreated patients with RRMS. After 24 months, 43 of the untreated patients switched to DMDs. The four groups of patients were followed up for an additional 24 months. At 48 months the mean standard deviation number of new CLs was significantly lower in patients treated with sc IFNβ-1a (1.4 ± 1.0, range 0–5) compared with im IFNβ-1a (2.3 ± 1.3, range 0–6,) and glatiramer acetate (2.2 ± 1.5, range 0–7,). Significant reductions in CL accumulation and new white matter and gadolinium-enhancing lesions were also observed in the 43 patients who switched to DMDs after 24 months, compared with the 24 months of no treatment. Concluding, this study confirms that DMDs significantly reduce CL development and cortical atrophy progression compared with no treatment.
Keywords
Funding Information
- Merck
This publication has 23 references indexed in Scilit:
- The changing clinical course of multiple sclerosis: A matter of gray matterAnnals of Neurology, 2013
- The predictive value of gray matter atrophy in clinically isolated syndromesNeurology, 2011
- A case of multiple sclerosis presenting with inflammatory cortical demyelinationNeurology, 2011
- Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosisMultiple Sclerosis Journal, 2011
- Extent of cerebellum, subcortical and cortical atrophy in patients with MS: A case-control studyJournal of the Neurological Sciences, 2009
- Accumulation of cortical lesions in MS: relation with cognitive impairmentMultiple Sclerosis Journal, 2009
- Cortical atrophy is relevant in multiple sclerosis at clinical onsetZeitschrift für Neurologie, 2007
- Gray and white matter volume changes in early RRMSNeurology, 2005
- Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Estimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot DesignsJournal of Educational Statistics, 1976